Status:
COMPLETED
TTHX1114(NM141) in Combination With DWEK/DSO
Lead Sponsor:
Trefoil Therapeutics, Inc.
Conditions:
Fuchs' Endothelial Dystrophy
Fuchs Dystrophy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Open label, single-treatment, with a concurrent non-treatment control
Eligibility Criteria
Inclusion
- Key
- Fuchs Endothelial Cell Dystrophy (FECD) diagnosed more than 6 months
- Scheduled for DWEK/DSO with a planned central descemetorhexis of approx 4 to 5 mm
- Subjects in Group 2 must have a stable Fellow Eye with adequate function
- Key
Exclusion
- Secondary corneal/ocular pathology in the Study Eye
- Prior refractive surgery in the Study Eye
- Prior exposure to TTHX1114
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2023
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04676737
Start Date
February 1 2021
End Date
January 13 2023
Last Update
November 7 2023
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Trefoil Investigational Site 124
Long Beach, California, United States, 90805
2
North Bay Eye Associates
Petaluma, California, United States, 94954
3
Trefoil Investigational Site 123
Deerfield Beach, Florida, United States, 33064
4
Trefoil Investigational Site 119
Fort Myers, Florida, United States, 33907